Merck KGaA (MKGAY.PK) said the European Commission or EC has approved extension of the indication of Rebif, a treatment for relapsing forms of multiple sclerosis or MS. This EC approval, based on REFLEX study results, is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS.
Annalisa Jenkins, Head of Global Drug Development and Medical at the Merck Serono division. "Multiple sclerosis has an initial stage when clinical manifestations are not pronounced but irreversible neurological damage is taking place. Throughout the European Union, neurologists will now be able to prescribe Rebif for patients with early signs of this devastating disease."
The new labelling for Rebif is valid immediately in all 27 member states of the European Union. The company still invests in discovering and developing treatment options in this area, including active life-cycle management initiatives for Merck's foundation therapy, Rebif, as well as strengthening its existing and establish new collaborations to advance research and bring innovative solutions to patients living with MS.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.